Back to discover

Protein / target

Fusion glycoprotein F0

FQ89535Human respiratory syncytial virus
4
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Entry receptor-mediated virion attachment to host cell

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Inactive precursor that is cleaved at two sites by a furin-like protease to give rise to the mature F1 and F2 fusion glycoproteins

Subcellular location

Host Golgi apparatus membraneHost cell membraneVirion membrane
Domains and Gene Ontology detail (8)

Gene Ontology

  • Chost cell Golgi membrane
  • Chost cell plasma membrane
  • Cviral envelope
  • Cvirion membrane
  • Pentry receptor-mediated virion attachment to host cell
  • Pfusion of virus membrane with host plasma membrane
  • Psymbiont entry into host cell
  • Psymbiont-mediated induction of syncytium formation

574 aa · 63 kDa

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

clesrovimab
Narrow target profileInhibitor

Fusion glycoprotein F0 inhibitor

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

4

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2026-04-15

    Approval: Enflonsia (EMA)

    ema · regulatory · ema · via clesrovimab

  2. New publication2025-03-01
    A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.

    The Journal of infectious diseases · 2025 · 28 citations · Europe PMC · via clesrovimab

  3. New publication2025-03-01
    Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150.

    The Journal of infectious diseases · 2025 · 5 citations · Europe PMC · via clesrovimab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.